Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

<b>Background:</b> Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-t...

Full description

Bibliographic Details
Main Authors: Martina Catalano, Ugo De Giorgi, Marco Maruzzo, Davide Bimbatti, Sebastiano Buti, Giulia Mazzaschi, Giuseppe Procopio, Matteo Santoni, Luca Galli, Raffaele Conca, Laura Doni, Lorenzo Antonuzzo, Giandomenico Roviello
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Biomedicines
Subjects:
renal cell carcinoma
TKI
good risk
poor risk
Online Access:https://www.mdpi.com/2227-9059/10/10/2444

Internet

https://www.mdpi.com/2227-9059/10/10/2444

Similar Items